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Abstract: Background: Smoking tobacco is disproportionably common among HIV-infected patients in the highly active 
antiretroviral therapy (HAART) era. Methods: An observational cohort study of 300 HIV-positive patients receiving care 
between 1996 and 2005 examined the effect of smoking on pneumonia risk. Multivariable analyses assessed the associa-
tion between smoking and pneumonia risk and identified independent predictors of pneumonia during the HAART era. 
Results: Current smoking was common (67%). Eighty-two patients (27%) experienced 119 pneumonia episodes during 
2151 patient-years of follow-up, with 7.2 episodes/100 person-years among smokers and 2.9 episodes/100 person-years 
among non-smokers (unadjusted incidence rate ratio (IRR): 2.50 (95% CI: 1.58, 4.09). Adjustment for age and HIV RNA 
level resulted in an IRR of 1.77 (95% CI: 0.98, 3.21). No prior antiretroviral therapy use (P-value <0.001), higher HIV 
RNA level (P-value = 0.01), lower CD4 count (P-value = 0.01), younger age (P-value = 0.01), and alcohol use (P-value = 
0.04) were independent predictors of pneumonia. HAART use decreased pneumonia risk (IRR 0.28, 95% CI: 0.18, 0.44). 
Conclusions: While HIV-positive smokers had over a 2-fold increase in the rate of pneumonia, the trend did not reach sta-
tistical significance in multivariable models. Clinical factors such as HAART, alcohol use and immunological status are 
important in pneumonia risk. 
INTRODUCTION 
  Smoking tobacco is a major public health concern, with 
numerous adverse health effects, including increased risks of 
lung cancer, heart disease, peripheral vascular disease, la-
ryngeal cancer, oral cancer, esophageal cancer, chronic ob-
structive pulmonary disease, and respiratory infections [1]. 
In the US, smoking is responsible for nearly 430,000 deaths 
each year [1, 2]. Although smoking has been declining in the 
general population [3], tobacco smoking among people liv-
ing with HIV remains high with estimates ranging from 39-
70% [4-9]. 
  Prior to the availability of highly active antiretroviral 
therapy (HAART), smoking increased the risk of bronchitis, 
hairy leukoplakia, oral candidiasis, oral warts, bacterial 
pneumonia, and pneumococcal bacteremia [6, 10-13], but 
did not appear to affect progression to an AIDS defining 
clinical condition or mortality [4, 14-18]. Even though 
pneumonia continues to be an important clinical condition 
among HIV-infected patients receiving HAART [19, 20], the 
effect of smoking on respiratory morbidity since the avail-
ability of potent antiretroviral combination therapies remains 
largely unknown. Additionally, few studies have focused on 
identifying additional risk factors for pneumonia in HIV-
infected patients exclusively during the HAART era. There-
fore, we conducted the present study among HIV-infected 
individuals receiving HIV care at a tertiary hospital in the 
Southeastern United States between January 1, 1996 and 
September 1, 2005 to: (1) assess the association between   
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smoking tobacco and the risk of developing pneumonia; and 
(2) identify independent predictors of developing pneumo-
nia. 
MATERIALS AND METHODOLOGY 
Study Population 
  Patients were eligible to participate if they were enrolled 
in the University of North Carolina Center for AIDS Re-
search (UNC-CFAR) HIV Clinical Cohort Study, completed 
a comprehensive in-person interview, the Clinical Socio-
Demographic and Behavioral Survey (CSDBS), and received 
HIV care between January 1, 1996 and September 1, 2005. 
Data collection for the observational clinical cohort study 
include electronic transfer of institutionally available data 
and periodic comprehensive standardized medical record 
reviews [21]. The CSDBS asks patients about social, demo-
graphic, and behavioral factors generally not consistently 
available in medical records, including detailed smoking 
history. 
Pneumonia 
  For patients completing the CSDBS, the UNC-CFAR 
database was interrogated to identify all pneumonia events 
among study participants through abstraction of chart diag-
noses. A retrospective chart review was then performed for 
all pneumonia events and classified by a pulmonary physi-
cian (DMM). Bacterial pneumonia was classified as “prob-
able” or “confirmed.” Probable bacterial pneumonia re-
quired: (1) a medical diagnosis of pneumonia, including at 
least three clinical signs and symptoms (e.g., temperature 
>38.0°C, heart rate >100 beats/minute, respiratory rate >22 
breaths/minute, consolidation on exam, cough, fever, shak-
ing chills, pleuritic chest pain, and/or shortness of breath); Smoking and Predictors of Pneumonia Among HIV-Infected Patients  The Open Respiratory Medicine Journal, 2008, Volume 2    23 
(2) a chest radiograph with a new infiltrate; and (3) a posi-
tive clinical response to antibiotic therapy. Confirmed bacte-
rial pneumonia required the above criteria and isolation of an 
organism by sputum Gram stain and culture, diagnostic 
bronchoalveolar lavage (BAL), positive blood culture, or a 
positive  Streptococcus pneumoniae or  Legionella pneumo-
phila urine antigen. 
  Probable and confirmed diagnoses of Pneumocystis ji-
rovecii  pneumonia (PCP) were defined as for bacterial 
pneumonia above in the appropriate clinical setting, with 
confirmed PCP requiring evidence of P. jirovecii on micro-
scopic examination of BAL or sputum specimens. A pulmo-
nary mycobacterial infection was defined as a compatible 
clinical and chest radiograph presentation with isolation and 
culture of a typical respiratory mycobacterium from two or 
more sputum cultures or isolation in BAL or bronchial wash-
ings warranting appropriate anti-mycobacterial therapy. 
Smoking 
  Since the immunological effects of smoking on the respi-
ratory tract are likely not permanent, we elected to use cur-
rent smoking and ignore history of smoking. Current smok-
ing was assigned based on the self- reported current smoking 
reported at the time of the CSDBS interview. We subtracted 
the duration of smoking (pack-years) from the CSDBS inter-
view date to avoid misclassification. Since patients contrib-
uted time before and after the CSDBS interview, and be-
cause the median number of years smoking in the study 
population was 20 years (Interquartile range (IQR): 15, 28), 
we carried the latest smoking status forward. 
Covariates 
  For the first aim of this study we considered a number of 
clinical and demographic characteristics as possible effect 
measure modifiers or confounders of the association between 
smoking and risk of pneumonia. Covariates included sex, 
race, age, intravenous drug use (IVDU), alcohol abuse, crack 
cocaine abuse, vaccination history, HAART use, CD4 cell 
counts, and HIV RNA levels. Vaccination was defined as 
receiving an influenza vaccine within the prior one year or a 
pneumovax vaccine in the prior five years [22]. Intravenous 
drug use (IVDU), crack cocaine use, and alcohol abuse were 
based on self-reported behavior on the CSDBS and medical 
record reviews. These same factors were also included in the 
second aim of this study to identify independent predictors 
of pneumonia incidence. 
Statistical Analyses 
  Patient follow-up (person-time at risk) began on the latter 
of January 1st, 1996 or the date of entry to HIV care, and 
ended on the earlier of September 1st, 2005 or the last HIV 
clinic visit. All factors which vary over time were calculated 
relative to study entry, each pneumonia event, and end of 
follow-up. Crude incidence rates for pneumonia were calcu-
lated by dividing the number of pneumonia events by per-
son-time at risk and expressed as number of pneumonia 
cases per 100 person-years. 
  Demographic and clinical characteristics were contrasted 
by current smoking status relying on basic descriptive statis-
tics, including the chi-square test for categorical variables 
and the Mann-Whitney test for continuous variables. Strati-
fied analyses included calculating incidence rate ratios (IRR) 
and 95% confidence intervals (CI) for the effect of smoking 
on the rate of pneumonia within different strata of patient 
characteristics. Since each patient could have experienced 
more than one pneumonia event during follow-up, we fit 
multivariable Poisson distribution log-linear regression mod-
els with generalized estimating equations (exchangeable 
working correlation matrix) to account for repeat measures. 
  The first aim of this study was to arrive at the least biased 
estimate of the effect of smoking on the incidence rate of 
pneumonia in a subset of HIV-infected patients in the UNC 
CFAR cohort. We first fit a full model containing all factors 
identified in stratified analyses as either potential effect 
measure modifiers or confounders for the association be-
tween smoking and pneumonia. Interaction terms with P-
values 0.20, indicated effect measure modification. Using a 
hierarchical backwards elimination procedure, covariates 
which changed the unadjusted estimate by at least 10%, indi-
cating appreciable confounding, were retained in the final 
model. The 10% change-in-estimate was calculated as ln | 
IRRFULL / IRRREDUCED |. 
  The second aim of this study was to estimate independent 
predictors of acquiring pneumonia. We first fit a full model 
including all covariates that were associated with pneumonia 
as indicated by a P-value <0.05 in bivariate analyses. Factors 
which did not independently predict pneumonia based on an 
a priori significance level of <0.05 were removed using a 
hierarchical backwards elimination procedure. Only those 
variables with P-values <0.05 were retained in the final pre-
dictive model. All analyses were performed using STATA 
version 8.2 (College Station, Texas, USA). The study was 
reviewed and approved by the institutional review board. 
RESULTS 
Study Population 
  Between January 1996 and September 1, 2005, 1849 pa-
tients were enrolled in the UNC-CFAR Clinical Cohort 
Study. Among these, 303 completed the CSDBS interview. 
We excluded 3 patients because of missing CD4 cell counts 
or HIV RNA levels. The 300 patients included in this study 
contributed 2151 person-years of follow-up during the study 
period, for a median of 6.9 years of follow-up [IQR: 4.6, 
9.2]. Two-thirds were men (67%), 76% were African Ameri-
can and 24% White. The median age was 44 years (IQR: 38, 
48). Substance abuse was common, with a high proportion of 
patients reporting prior and/or current alcohol abuse (60%), 
crack-cocaine use (73%), or IVDU (20%). During follow-up 
almost all patients received antiretroviral therapy (83%) and 
55% received an influenza and/or pneumococcal vaccine. 
With the exception of a longer duration since HIV diagnosis, 
the CSDBS subjects in this study are clinically and demog-
raphically representative of the overall UNC CFAR cohort 
[21]. 
Pneumonia Diagnosis 
  Eighty-two patients (27%) were diagnosed with 119 epi-
sodes of pneumonia for an overall incidence rate of 5.5 per 
100 person-years (95% CI: 4.6, 6.6). The majority of pneu-
monias were bacterial (61%), with Streptococcus pneumo-
niae being the most commonly isolated organism (Table 1). 
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one-third (34%) of pneumonia diagnoses. Of the PCP cases, 
44% were on HAART at diagnosis. The diagnosis of myco-
bacterial infections in this cohort was uncommon, represent-
ing only 4.2% of pneumonia diagnoses. 
  Fifty of the 119 pneumonia events (42%) were con-
firmed, including 56% of PCP cases, 35% of bacterial 
pneumonia cases, and all mycobacterial cases. At the time of 
the pneumonia event the median CD4 cell count was 193 
cells/mm
3 (IQR: 35, 424) among patients with bacterial 
pneumonias and 35 cells/mm
3 (IQR: 13, 118) among patients 
with PCP (P-value < 0.001). 
Table 1.  Clinical Characteristics of 119 Pneumonia Episodes 
Diagnosed in 82 HIV-Infected Patients, from Janu-
ary 1, 1996 to September 1, 2005 
 
N (%) 
Total 
119 (100%) 
Bacterial pneumonia    78 (66%) 
 Probable  51 (65%) 
 Confirmed  27 (35%) 
 Streptococcus pneumoniae   10 
 Legionella pneumophila   3 
 Haemophilus influenzae   3 
 MSSA   2 
 Nocardia sp.   2 
 Pseudomonas sp.   1 
 MRSA   1 
 M. tuberculosis   1 
 M. avium-intracellulare (MAC)   3 
 M. kansasii   1 
Pneumocystis jirovecii pneumonia (PCP)   41 (34%) 
 Probable  18 (44%) 
 Confirmed  23 (56%) 
 DF: Done – positive*   14 
 Done – negative   16 
 Not done   11 
 BAL cytology:   Done – positive*   10 
                            Done - negative   6 
                            Not done   25 
MSSA, Methicillin-sensitive Staph aureus; MRSA, Methicillin-resistant Staph aureus; 
DF, Direct immunofluorescence stain; BAL, Broncho-alveolar lavage; *Includes one 
patient with a positive DF and BAL cytology. 
 
Smoking Prevalence and Characteristics of HIV-Infected 
Smokers 
  Most patients (N=241, 80%) reported ever having 
smoked tobacco for at least six months, and reported a me-
dian of 20 years of smoking (IQR: 15, 28), 10 cigarettes per 
day (IQR: 5, 20), and 10 pack-years of smoking exposure 
(IQR: 5, 20). At the time of the interview 63% (N=188) re-
ported currently smoking tobacco. On bivariate analysis,   
 
smokers were more likely to be male, to use other substances 
of abuse such as alcohol, intravenous drugs, and cocaine 
(Table 2). Additionally, median CD4 cell counts were lower 
in smokers compared to non-smokers (351 cells/mm
3 versus 
490, respectively; P-value = 0.01) and HIV RNA levels were 
higher (2.8 log10 copies/mL versus 1.9, respectively; P-value 
= 0.01). 
Effect of Smoking on Pneumonia Incidence Rates 
  The majority of pneumonia episodes occurred among 
smokers (95 of 119; 80%). The incidence rate of pneumonia 
among smokers was 7.2 per 100 person-years (95% CI: 5.8, 
8.8) in comparison to 2.9 (95% CI: 1.8, 4.3) among non-
smokers, for an unadjusted incidence rate ratio (IRR) of 2.5 
(95% CI: 1.58, 4.09). Effect measure modifiers were not 
identified. Age and most proximal HIV RNA level were the 
only confounders of the association between smoking and 
pneumonia incidence, and were retained in the final model. 
The adjusted incidence rate ratio for smoking was 1.77 (95% 
CI: 0.98, 3.21; P-value = 0.06) (Table 3). 
Independent Predictors of Pneumonia 
  For the second aim, a number of patient characteristics 
were predictive of developing pneumonia in bivariate analy-
ses, including smoking, African American race, younger age, 
alcohol use, crack cocaine use, antiretroviral use, a lower 
CD4 cell count and higher HIV RNA level (Table 4). In mul-
tivariable analyses, younger age, alcohol use, lack of antiret-
roviral use, a lower CD4 cell count, and a higher HIV RNA 
were identified as independent predictors of pneumonia 
among all patients (Table 5). Antiretroviral therapy use was 
highly protective of developing pneumonia (IRR 0.28). CD4 
cell count was inversely associated with pneumonia inci-
dence (for each 100 CD4 cell count increase the incidence 
rate decreased by 16% (IRR = 0.84). HIV RNA level was 
directly associated with an increase in pneumonia incidence 
rate (1.52 fold increase for each 1 log10 HIV RNA level in-
crease). Consistent with the first study aim, smoking in-
creased the risk of pneumonia but the trend did not reach 
statistical significance in the multivariable model (IRR 1.77, 
95% CI: 0.99, 3.15). 
DISCUSSION 
  We observed a high burden of pneumonia among people 
living with HIV and receiving care in the Southeastern US 
between 1996 and 2005. More than one in four (27%) pa-
tients had at least one pneumonia episode during an average 
of seven years of follow-up. 
  The majority of pneumonias were bacterial (61%), but a 
substantial number (35%) were PCP. Consistent with other 
studies, we observed an extremely high burden of tobacco 
use in this cohort. This observation suggests that, despite 
advances in HIV care [6, 23], respiratory infections continue 
to be a problem among people living with HIV in the US and 
tobacco use is disproportionably high in this population. 
  The majority (80%) of pneumonia episodes occurred 
among smokers. The estimated incidence rate of pneumonia 
among smokers was 7.2 per 100 person-years versus 2.9 in 
non-smokers. Smoking is reported to be associated with an 
increased risk of pneumonia in HIV-infected patients prior to  
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Table 3.  Multivariate Poisson Model Estimates of the Effect 
of Smoking on Pneumonia Incidence Rates in 300 
HIV-Infected Patients Receiving Care Between 
January 1996 and September 1, 2005 
 
Covariate* IRR  95%  CI  p-Value 
Current smoker  1.77  0.98, 3.21  0.060 
Age, per 10 year increase  0.62  0.41, 0.93  0.019 
HIV RNA level, per 1 log10 
increase 
1.96 1.64,  2.38  <0.001 
*All factors which vary over time were measured at a pneumonia event among those 
who had pneumonia and at the last clinic visit among those who did not experience 
pneumonia; IRR, incidence rate ratio; CI, confidence interval. 
 
the use of potent combination antiretroviral therapies [13, 14] 
and in studies that span the pre-HAART and HAART eras 
[24]. The lack of association between smoking and pneumonia 
observed in this study may be a result of patients exclusively 
from the HAART era, the high proportion (83%) of HAART 
use, the relatively small sample size, and the small proportion 
of never smokers in this cohort. Additionally, the inclusion of 
PCP, which may be affected more by CD4 cell counts and 
HAART use rather than by smoking, may have affected the 
observed association. However, even though smoking was not 
an independent predictor of pneumonia in this study popula-
tion, the two fold increase in incidence rates combined with 
the extremely high prevalence of smoking suggests that smok-
ing cessation should be an important intervention to reduce the 
burden of pneumonia among people living with HIV, particu-
larly since smoking negatively impacts on morbidity and mor-
tality in this population [23]. 
  The increased risk of pneumonia in smokers may be ex-
plained by a number of studies of smoking in both immuno-
competent and HIV-infected individuals. In immunocompe-
tent individuals, smoking impairs ciliary function [25], 
which may result in pathogen colonization and airway in-
flammation [26, 27]. In addition, nicotine has been shown to 
suppress leukocyte migration, and cigarette smoke is directly 
cytotoxic to alveolar type II cells [28, 29]. Compared to 
HIV-infected non-smokers, HIV-infected smokers demon-
strate decreased levels of secreted proinflammatory cytoki-
nes interleukin-1 (IL-1) and IL-6 by lung macrophages [30] 
and reduced concentrations of IL-1 and TNF- in BAL 
fluid [31]. Furthermore, alveolar macrophages recovered 
from HIV-positive smokers demonstrate decreased phago-
cytic function to both Escherichia coli bacteria and IgG-
opsonized sheep red blood cells compared to HIV-infected 
non-smokers [32]. These data may partially explain why 
smoking as an independent risk factor for invasive pneumo-
coccal disease in HIV-infected and uninfected cohorts [12, 
33]. 
Table 2.  Demographic and Clinical Characteristics of 300 HIV-Infected Patients Stratified by Smoking Status 
 
Characteristic*  Smokers (N = 188)  Non-Smokers (N = 112)  p-Value
± 
Age (yr), med (IQR)  44 [40, 49]  45 [38, 51]  0.361 
Men, n (%)  135 (72)  65 (58)  0.015 
Race, n (%)       
 African American  145 (77)  83 (74)  0.560 
Time since HIV diagnosis (yrs), med (IQR)  9 [7, 14]  10 [7, 13]  0.549 
MSM, n (%)  54 (29)  34 (30)  0.764 
Alcohol use, n (%)       
 Previous use  89 (47)  31 (28)  <0.001 
 Current use  50 (27)  11 (10)  <0.001 
Intravenous drug use, n (%)       
 Previous use  40 (21)  13 (12)  0.034 
 Current use  7 (4)  0 (0)  0.048 
Crack cocaine use, n (%)       
 Previous use  105 (56)  34 (30)  <0.001 
 Current use  68 (36)  12 (11)  <0.001 
Antiretroviral use, n (%)  156 (83)  92 (82)  0.853 
Time on antiretroviral therapy (yrs), med (IQR)  9 [6, 11]  9 [7, 12]  0.316 
Number of prior antiretrovirals, med (IQR)  4 [3, 6]  4 [3, 7]  0.139 
Vaccination status, n (%)  105 (56)  62 (55)  0.934 
CD4 cell count (cells/mm
3), med (IQR)  351 [151, 630]  490 [272, 656]  0.012 
HIV RNA level (log10 copies/ml), med (IQR)  2.8 [1.7, 4.4]  1.9 [1.7, 4.1]  0.015 
*All factors which vary over time were measured at the last pneumonia event among those who had pneumonia and at the last clinic visit among those who did not experience pneu-
monia; med, median; IQR, interquartile range; MSM, men who have sex with men; ± p-value for Chi-square test for independence, t-test for equality of means using pooled variance 
procedures, or Wilcoxon-Mann-Whitney test, as appropriate, values  0.05 considered significant. 26    The Open Respiratory Medicine Journal, 2008, Volume 2  Murdoch et al. 
 
  To better understand how the burden of pneumonia in the 
HAART era could be further reduced, the second study aim 
identified independent predictors other than smoking for 
developing pneumonia among people living with HIV. 
Antiretroviral use was highly protective and, consistent with 
previous observations [13, 14, 19, 20, 24], a low CD4 cell 
Table 4.  Pneumonia Incidence Rates Among 300 HIV-Infected Patients Stratified by Demographic and Clinical Characteristics 
 
Characteristic*  Pneumonia Events  Person-Time  Incidence Rate (95% CI)  p-Value 
Smoking status         
 Nonsmoker  24  833  2.9 (1.8, 4.3)  <0.001 
 Current smoker  95  1318  7.2 (5.8, 8.8)   
Race        
 White  14  546  2.6 (1.4, 4.3)  <0.001 
 Racial/Ethnic Minority  105  1605  6.5 (5.3, 7.9)   
Gender        
 Female  33  665  5.0 (3.4, 7.0)  0.461 
 Male  86  1486  5.8 (4.6, 7.1)   
Age        
 18-35  27  283  9.5 (6.3, 13.9)  <0.001 
 36-44  57  744  7.7 (5.8, 9.9)   
 45  35  1125  3.1 (2.2, 4.3)   
Intravenous drug use         
 No  90  1726  5.2 (4.2, 6.4)  0.214 
 Yes  29  425  6.8 (4.6, 9.8)   
Alcohol use         
 No  47  1132  4.1 (3.0, 5.5)  0.004 
 Yes  72  1018  7.1 (5.5, 8.9)   
Crack cocaine use         
 No  46  1084  4.2 (3.1, 5.7)  0.010 
 Yes  73  1067  6.8 (5.4, 8.6)   
Vaccination status         
 No  66  927  7.1 (5.5, 9.1)  0.070 
 Yes  53  1224  4.3 (3.2, 5.7)   
Antiretroviral use         
 No  45  291  15.5 (11.3, 20.7)  <0.001 
 Yes  74  1860  4.0 (3.1, 5.0)   
CD4 cell count (cells/mm
3)        
 350  29  1189  2.4 (1.6, 3.5)  <0.001 
 200-349  13  398  3.3 (1.7, 5.6)   
 50-199  32  342  9.4 (6.4, 13.2)   
 <50  45  222  20.3 (14.8, 27.1)   
HIV RNA level (copies/ml)         
 <400  19  1130.7  1.7 (1.0, 2.6)  <0.001 
 400-9,999  18  379.9  4.7 (2.8, 7.5)   
 10,000-99,999  35  417.5  8.4 (5.8, 11.6)   
 100,000  47  222.8  21.1 (15.5, 28.0)   
* All factors which vary over time were measured at a pneumonia event among those who had pneumonia and at the last clinic visit among those who did not experience pneumonia. Smoking and Predictors of Pneumonia Among HIV-Infected Patients  The Open Respiratory Medicine Journal, 2008, Volume 2    27 
count was significantly associated with pneumonia risk. 
These data indicate the importance of early diagnosis of HIV 
infection and access to care prior to the development of se-
vere immunosuppression. In contrast to previous observa-
tions [13, 19, 20, 34], intravenous drug use was not predic-
tive of pneumonia in bivariate or multivariate analyses, pos-
sibly as a result of the relatively low use in this cohort. 
Younger age was predictive of pneumonia risk, which may 
be partially explained by early AIDS-related diagnoses at 
entry to HIV care in this population [35]. Interestingly, alco-
hol use was identified as a predictor of pneumonia in the 
predictive modeling analyses. This observation is important 
because alcohol use among HIV-infected patients is high, is 
often associated with other substance abuse [36, 37], and is 
associated with pneumonia in HIV-uninfected cohorts [38]. 
Table 5.  Independent Predictors of Pneumonia Among 300 
People Living with HIV in the Southeastern US, 
1996-2005 
 
Characteristic* IRR  95%  CI  p-Value 
Alcohol use  1.67  1.02, 2.72  0.04 
Antiretroviral use  0.28  0.18, 0.44  <0.001 
Age, per 10 year increase  0.57  0.37, 0.89  0.01 
CD4 cell count, per  0.84  0.74, 0.96  0.01 
100 cell/mm
3 increase       
HIV RNA level, per 1 log10 increase  1.51 1.19,  1.93 <0.001 
*All factors which vary over time were measured at a pneumonia event among those 
who had pneumonia and at the last clinic visit among those who did not experience 
pneumonia; IRR, incidence rate ratio; CI, confidence interval. 
 
  This analysis was limited by several factors. First, the 
diagnosis of pneumonia was made as part of routine care, 
and without bacteriological confirmation in 53% of cases. 
Increased rates of bronchitis and non-specific respiratory 
complaints in smokers may have led to misclassification of 
these subjects as pneumonia events. However, the use of 
chest radiographs minimized this bias. Second, this analysis 
relied on self-reported behaviors during the CSDBS inter-
view. However, based on experiences in other studies, the 
self-reported current smoking status and amount of smoking 
measured in pack-years was unlikely to be biased [39, 40]. 
To minimize the impact of self-reported behavior, we at-
tempted to corroborate self-reported behaviors with clinical 
diagnoses. Third, we were not able to adequately control for 
the use of opportunistic infection prophylaxis and antimicro-
bial use during the observation period. Attempts to control 
for these factors resulted in collinearity with antiretroviral 
use and unstable model estimates. Lastly, subjects who com-
pleted the CSDBS questionnaire represented a subset of the 
overall CFAR cohort. With the exception of a longer dura-
tion since HIV diagnosis, the CSDBS subjects in this study 
are clinically and demographically representative of the 
overall UNC CFAR cohort [21]. 
CONCLUSIONS 
  With the introduction of highly active antiretroviral ther-
apy (HAART), significant declines in the burden of pneu-
monia have occurred in people living with HIV. However, 
despite these declines, smoking and other substance abuse 
remains high, with increased incidences of pneumonia 
among smokers and those who report alcohol use. This ob-
servation, coupled with the increased risk in those presenting 
with advanced immunosuppression, suggest that early access 
to HIV care programs incorporating substance abuse treat-
ment programs may further reduce the burden of pneumonia 
among people living with HIV. 
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